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Background: We examined data from a Phase 2 trial {NCT00457821} of ivacaftor, a CFTR potentiator, in cystic ﬁbrosis (CF) patients with a
G551D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential
difference (NPD) to estimate CFTR activity.
Methods: Sweat chloride and NPD were secondary endpoints in this placebo-controlled, multicenter trial. Standardization of sweat collection, processing,
and analysis was employed for the ﬁrst time. Sweat chloride and chloride ion transport (NPD) were integrated into a model of CFTR activity.
Results: Within-patient sweat chloride determinations showed sufﬁcient precision to detect differences between dose-groups and assess ivacaftor
treatment effects. Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity
equivalent to approximately 35%–40% of normal.
Conclusions: Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Nasal potential difference; Variance; Sweat test1. Introduction
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http://dx.doi.org/10.1016/j.jcf.2013.09.007lishedbrane conductance regulator (CFTR) protein, which regulates
ion flux at the surface of certain epithelial cells [1]. Restoring
defective CFTR ion transport is a promising therapeutic approach
under evaluation in individuals with CF, creating a need for
suitable biomarkers of CFTR activity. In the clinical setting, the
most commonmethods to assess CFTR function are sweat chloride
concentration and nasal potential difference (NPD) [2]. Sweat
chloride is appealing as a biomarker because abnormalities occur
early, it can be measured consistently in patients at any age, and
sweat glands do not appear to be susceptible to secondary damageby Elsevier B.V. All rights reserved.
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and gastrointestinal tract) [2]. Sweat chloride is widely used as a
diagnostic tool for CF [3] and is substantially more convenient
and less costly to perform than NPD.
Ivacaftor is a CFTR modulator that potentiates the chloride
transport of several CF disease-causing forms of CFTR, including
G551D-CFTR [4,5]. The G551D-CFTR mutation, termed as
gatingmutation, results in a protein with severely restricted channel
opening but normal cell membrane expression levels [6]. A Phase
2, dose-ranging trial of ivacaftor was conducted in patients with CF
who have the G551Dmutation on at least 1 CFTR allele [7]. The
primary objective of this trial was to evaluate safety; however,
secondary endpoints included exploratory biomarkers of CFTR
function: sweat chloride concentrations and NPD testing. Patients
receiving ivacaftor achieved significant reductions in sweat
chloride when evaluated both within-patient (change from
baseline) and placebo controls.
Despite the development of best practices for sweat chloride
testing in the diagnosis of CF [8], multiple published reports in
the past 10 years have concluded that consistency and reliability
are poor across laboratories. Assessments performed worldwide
revealed numerous concerns, including lack of conformity to
guidelines, inadequate quality control measures, low numbers of
tests performed yearly, and inconsistencies in minimum sweat
volumes, iontophoresis solutions, and reference ranges [9,10].
In anticipation of the need for clinical testing of CFTR
potentiators, such as ivacaftor, in multicenter trials, the Cystic
Fibrosis Foundation Therapeutics Inc.—Therapeutic Development
Network, in collaboration with Vertex Pharmaceuticals, developed
standard operating procedures for sweat collection using the
Macroduct™ system (Wescor/ELITech Group, Logan, UT) with
the aim of minimizing variability across sites. Improvements
included standardization of protocols for: 1) sweat collection, 2)
frozen storage, 3) overnight transport to the central laboratory for
analysis, and 4) uniform training of personnel at all sites.
This Phase 2 ivacaftor study was the first to utilize these
new protocols. We examined reliability in sweat chloride data
by determining within- and between-patient variances. Finally,
published sweat chloride and NPD values were used to estimate
CFTR activity.
2. Methods
2.1. Study design
The design of this ivacaftor Phase 2 study is fully described
elsewhere [7]. Briefly, the study was a randomized, double-blind,
placebo-controlled, multicenter trial conducted in 2 parts. In Part 1,
20 patients with CF were randomized to receive either ivacaftor
every 12 h at doses of 25 mg, 75 mg, or 150 mg, or matching
placebo for 14 days in a crossover, dose-ascending format. In Part
2, 19 new patients were randomized to receive ivacaftor every 12 h
at doses of 150 mg or 250 mg, or placebo for 28 days. The study
enrolled adult patients with CF who had theG551Dmutation on at
least 1 CFTR allele and a forced expiratory volume in 1 s (FEV1)
of at least 40%. The primary study objective was to evaluate the
safety and tolerability of ivacaftor. Secondary endpoints includedsweat electrolyte concentration, NPD, pulmonary function testing,
and patient-reported health-related quality of life.
During Part 1, sweat and blood samples were collected at
screening and on days 1, 7, and 14 of each treatment period, and
at a follow-up visit. NPD testing was performed on days 1 and 14
of each treatment period and at a follow-up visit. In Part 2, sweat
samples were collected at screening and on days 1 (baseline), 3,
14, 21, and 28 of the treatment period and at a follow-up visit;
NPD was performed on days 1, 14, and 28.
2.2. Sweat chloride and NPD methodology
We adapted sweat collection methods previously used in
multicenter clinical studies. We developed standardized ap-
proaches for sweat collection and shipping to a central labo-
ratory for analysis, and examined the effects of freezing and
storage of sweat samples (see online supplement). Between-
and within-patient variances were computed. NPD testing was
performed as previously described [7]. Training and qualifica-
tion of NPD operators are described in the online supplement.
2.3. NPD as a surrogate for CFTR activity and %
CFTR estimation
We used three approaches to estimate the degree of improve-
ment in CFTR activity among patients treated with ivacaftor based
on sweat chloride concentrations and NPDmeasurements: 1. sweat
chloride measurements alone, 2. NPD measurements alone, and 3.
sweat chloride and NPD measurements considered together with
NPD as a surrogate of CFTR activity.
2.3.1. Sweat chloride measurements alone
In our first approach, we calculated the percentage change in
sweat chloride during the Phase 2 study, with pooling of treatment
groups where appropriate.
2.3.2. Nasal potential difference alone
In our second approach, we examined a linear relationship
between NPD and CFTR activity. We defined the absence
of CFTR activity (zero activity) as the chloride-free-plus-
isoproterenol NPD response in pancreatic insufficient (PI)
CF patients [11–13]. Although very minimal activity may be
maintained in these patients, it is likely below the limit of
detection of this assay. We defined full CFTR activity (100%) as
the chloride-free-plus-isoproterenol response in control, non-CF
individuals [14]. Using these definitions, % CFTR activity for
any group of patients can be calculated by the following equation:• % CFTR activity = (X − PI CF group) / (control − PI CF
group) ∗ 100, where
○ X is the chloride-free-plus-isoproterenol response for the
sample group;
○ PI CF group is the chloride-free-plus-isoproterenol response
in patients with CF who are PI (no measurable CFTR
activity); and
Fig. 1. Within- and between-patient variance in sweat chloride over repeated
measures by dose of ivacaftor and placebo. Data are shown for Parts 1 and 2 of
the clinical trial. Within-patient variances were similar across treatment groups,
indicating a consistent treatment effect in given individuals. Between-patient
variances were high in the treatment groups, indicating variable effects of
ivacaftor in different individuals.
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for the control group—patients without CF (100% CFTR
activity).
To estimate the effects of ivacaftor on CFTR activity, data
from the Phase 2 trial were analyzed retrospectively according
to the equation above. Reference values (control and PI CF) for
calculating % CFTR activity in patients treated with ivacaftor
were drawn from subjects evaluated during the pre-trial NPD
technician qualification program. NPD technicians at participating
centers were trained and tested; mean data from CF (n = 16) and
control (n = 17) subjects tested during this period are shown in
supplemental Fig. E1.
2.3.3. Sweat chloride and NPD measurements considered
together with NPD as a surrogate of CFTR activity
In our third approach, we used NPD measurements as a
surrogate for CFTR activity. The respiratory tract is a relevant
disease-affected target organ for intervention, and thus changes
in CFTR activity as measured by the NPD in the respiratory
tract (across numerous phenotypes and studies) were chosen for
comparison with sweat chloride. In this approach, we expanded
the % CFTR activity analysis by examining published studies
that reported data for NPD and sweat chloride in CF patients
with varying degrees of disease severity and control individuals
[15–24].
3. Results
3.1. Sweat chloride training, freezing and stability
A total of 36 sweat chloride collection technicians from 15
sites in 3 countries were successfully trained and participated.
The training included in-person sessions with observers who
certified the individual technicians. Each trainee had to send in a
valid collection specimen to the central lab prior to being ap-
proved for the trial. As shown in supplemental Fig. E2, sweat
electrolytes were not affected by overnight shipping. In addition,
sweat chloride and sodium were stable over 18 months when
stored at −70 °C (supplemental Fig. E3).
3.2. Variances in sweat chloride measures
Within-patient and between-patient variances for sweat
chloride values from Parts 1 (n = 20) and 2 (n = 19) of the
Phase 2 ivacaftor trial are shown in Fig. 1 as a function of dose.
Among patients treated with placebo, within-patient variance in
sweat chloride (19.3 [mmol/L]2 for Part 1 and 19.8 [mmol/L]2
for Part 2), was generally comparable to between-patient variance
(36.7 [mmol/L]2 in Part 1 and 3.1 [mmol/L]2 in Part 2). Among
all patients treated with ivacaftor, within-patient variancewas low
(65.2 [mmol/L]2 in Part 1 and 42.1 [mmol/L]2 in Part 2) relative
to the magnitude of the treatment effects (e.g., the median change
of −59.5 mmol/L with the 150 mg ivacaftor dose) in the range of
dosing levels studied here. Between-patient variances were high
(452.1 [mmol/L]2 in Part 1 and 358.3 [mmol/L]2 in Part 2) for
all patients treated with ivacaftor. The intraclass correlationcoefficient (ICC; variance between patients/total variance)
provides an estimate of the contribution of between-patient
variance. For all patients treated in the ivacaftor study, the ICC
indicated that the majority of variance came from differences
between patients (sweat chloride ICC = 0.92 in Part 1 and 0.94
in Part 2).3.3. Ivacaftor treatment, sweat chloride, NPD, and
CFTR activity
We took three approaches to estimate the degree of improve-
ment in CFTR activity among patients treated with ivacaftor based
on sweat chloride concentrations and NPD measurements.3.3.1. Sweat chloride measurements alone
First, we calculated the percentage change in sweat chloride
during the Phase 2 study. The percentage provides a linear ap-
proximation of functional gain in chloride ion transport through the
CFTR channel (Table 1). Using this approach, patients treated with
ivacaftor experienced improvements in chloride transport ranging
from 29% to 47% (compared with 2% for the placebo arm).3.3.2. Nasal potential difference alone
We used changes in NPD to determine CFTR activity with
ivacaftor treatment. The zero-chloride plus isoproterenol NPD
response was converted to a percentage of normal CFTR activity
(see Methods for equation). The zero-chloride plus isoproter-
enol responses obtained on Day 14 suggested that patients
treated with ivacaftor experienced gains in CFTR activity in
the range of 15% (at the 25 mg dose) to 43% (at the 250 mg
dose) (Table 2).
Table 1
Actual and percentage change from baseline in sweat chloride concentrations in
the Phase 2 ivacaftor trial.
Ivacaftor
dose
Phase 2 time
point
n Mean baseline
sweat chloride
from Phase
2 trial (mmol/L)
Change from
baseline in sweat
chloride
(mmol/L)
%
change
from
baseline
25 mg Part 1, Day 14
(Group A)
8 104.9 −32.9 31%
75 mg Part 1, Day 14
(Groups A & B)
14 100.7 −40.4 a 40%
150 mg Parts 1 & 2,
Day 14
16 98.8 −46.0 b 47%
250 mg Part 2, Day 14 7 94.9 −27.6 29%
Placebo Parts 1 & 2,
Day 14
12 102.9 2.0 a 2%
a Change from baseline available for 13 patients and 11 patients in the 75 mg
and placebo groups, respectively.
b For 150 mg dose, change from baseline in sweat chloride was −42.3 and
−52.6 mmol/L for Part 1 and Part 2, respectively.
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together with NPD as a surrogate of CFTR activity
In our third approach, sweat chloride and NPD findings were
related to historical data on CFTR activity among different pheno-
typic manifestations of CFTR-related disease (Table 3). In Fig. 2,
mean sweat chloride concentrations across a range of CFTR
disease severity categorizations (including controls without CF) are
plotted against the zero-chloride-plus-isoproterenol responses
(see Methods for details). NPD values from different populations
(starting with the most severely affected: CF patients who are PI,
pancreatic sufficient, carriers of known and atypical mutations)
were obtained from more than 20 published patient cohorts
(Table 3) [15–24] across the spectrum of mutation severity and
disease phenotypes.
Mean baseline CFTR activity for the ivacaftor study population
was comparable to that seen in patients with CF who are PI andTable 2
NPD chloride-free-plus-isoproterenol responses and conversion to % CFTR
activity at Day 14 in the Phase 2 ivacaftor trial.
Ivacaftor
dose
Source n NPD chloride-free
+ iso response, mV
(range)
NPD response
as % CFTR
activity a
25 mg Part 1, Day 14
(Group A)
8 1.0 (−5.3 to 9.0)
Placebo = 2.3 (−1.5 to 5.0)
3.5/22.6
15%
75 mg Part 1, Day 14
(Groups A and B)
16 −2.5 (−16.5 to 4.5)
Placebo = 0.9 (−5.5 to 5.0)
7/22.6
31%
150 mg Part 1 Day 14
(Groups A and B)
8 −2.1 (−7.8 to 4.8)
Placebo = 0.9 (−5.5 to 5.0)
6.6/22.6
29%
150 mg Part 2, Day 14 8 −2.5 (−7.5 to 0.3)
Placebo = 3.5 (0.3 to 7.0)
7/22.6
31%
250 mg Part 2, Day 14 7 −5.3 (−12.0 to 1.7)
Placebo = 3.5 (0.3 to 7.0)
9.8/22.6
43%
Definition of abbreviations: CF = cystic fibrosis; CFTR = cystic fibrosis
transmembrane conductance regulator; NPD = nasal potential difference.
a The reference values from the ivacaftor qualiﬁcation study for chloride-free-plus-
isoproterenol response were −18.1 mV (control non-CF) and 4.5 mV (PI-CF). %
CFTR activity was calculated as described in the Methods.display minimal chloride ion transport capacity. When graphed as
a function of sweat chloride and NPD, CFTR activity calculated
for patients treated with ivacaftor was essentially superimposable
upon the CFTR activity curve determined by genotype–phenotype
relationships (Fig. 2). This suggests that changes in NPD and sweat
chloride with ivacaftor are similar to those seen with different
CFTR phenotypes (and corresponding genotypes). To further
examine effects of ivacaftor on CFTR activity, we plotted change
in sweat chloride vs. change in chloride-free-plus-isoproterenol
NPD data for individual patients. As shown in supplementary Fig.
E4, placebo patients showed very little change in sweat chloride or
NPD, whereas patients with ivacaftor showed effects consistent
with increases in CFTR activity.
4. Discussion
Using data from a Phase 2 trial of ivacaftor, we have
demonstrated the utility of sweat chloride as a biomarker for
evaluating changes in CFTR activity in the clinical trial setting.
Similar to NPD response, sweat chloride levels have been
observed to respond rapidly to treatment with ivacaftor, making
them attractive biomarkers for monitoring a biologic effect
shortly after treatment initiation. With a short training program
and standardized protocols, technicians were able to collect
sweat chloride measurements with good reliability across multiple
study sites. Importantly, changes in sweat chloride concentrations
reflected active vs. placebo treatment and enabled the evaluation of
dose-specific effects. This was the first validation of standardized
protocols and procedures for testing sweat chloride as an outcome
measure in a multicenter clinical trial of a CFTR potentiator.
We found low variance in sweat chloride concentrations
(both within- and between-patient) in patients treated with placebo.
Low variance was also present for the within-patient measures of
sweat chloride following ivacaftor treatment, whereas between-
patient variance was high. The higher between-patient variance,
when compared with within-patient variance, suggested that
patients responded differently to ivacaftor. The low within-patient
variance during treatment indicates that the response in a given
patient was relatively stable over the treatment period.
Given that ivacaftor is the first agent associated with large
magnitude reductions in sweat chloride in patients with CF, we
found limited published data to provide direct context for these
findings. Among the few published studies of agents designed
to modulate CFTR activity, the majority did not measure sweat
chloride [25], one reported very small changes (5 mmol/L after
10 weeks of lithium chloride) [26], and another did not measure
variability [27].
Data from a multicenter clinical trial evaluating changes
in sweat chloride and NPD in patients with CF treated with a
CFTR trafficking modulator, CPX (adenosine A1 receptor 8-
cyclopentenyl-1,3-dipropylxanthine), are generally consistent
with our findings [28]. Although no efficacy was seen with CPX,
the authors evaluated within- and between-patient variances across
their 4 participating study sites. Our variances were lower than
those in the CPX study, perhaps because of standardization of
techniques. The variances in the patients treated with placebo in
our study may provide a benchmark for future studies.
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patients in the ivacaftor treatment groups include differences
between the time of drug administration and the time of sweat
chloride collection, differences in the amount of CFTR activity
correction in individual patients, and variability in ivacaftor
exposure between patients. Possible reasons for differences in
the amount of ion transport correction include the specific
non-G551D mutation in the other allele, the relative quantity of
CFTR channels at the cell surface, and/or the role of modifier
genes impacting ion balance. The importance of these
differences in degree of sweat chloride changes and how
these result in a clinical benefit is not known.
The change in sweat chloride across dosing groups suggests
a non-linear relationship between sweat chloride and CFTR
activity. To estimate the degree of CFTR functional activity in
patients treated with ivacaftor, we related sweat chloride to
NPD. We included patient data from multiple published studies
of children and adults (excluding infants) with varying CF
phenotypes to better characterize the relationship between
genotype/phenotype and CFTR activity.
The treatment effect with ivacaftor in all four dosing groups
was closely aligned with the CFTR activity observed in
previously published studies, which supports a consistent
relationship between CFTR activity, disease manifestations,
and response to a CFTR potentiator. Patients with CF treated
with ivacaftor for 14 days achieved CFTR activity levels
corresponding to approximately 35% (with 75 mg and 150 mg)
and 40% (with 250 mg) of non-CF controls. This magnitude of
improvement is also consistent with that predicted in a previous
publication based on in vitro research with ivacaftor [4].
Investigators tested transmembrane potential differences using
primary cultures of human bronchial endothelial (HBE) cells
from patients with CF (G551D/F508del) and controls without
CF. When stimulated, the potential change in G551D/F508del
HBE cells was approximately 5% of that seen with non-CF
HBE cells, and in the presence of ivacaftor, rose to
approximately 48% of control HBE cells.
The model of sweat chloride and NPD presented here is
consistent with sweat chloride biomarker data drawn from
disparate published trials in patients with varying degrees of CF
disease severity. It brings an additional dimension to sweat
chloride as a biomarker by demonstrating that estimates of
CFTR activity that integrate NPD responses produce findings
comparable to those obtained with sweat chloride alone.
Finally, the close alignment between data from patients treated
with ivacaftor and historical controls provides verification of
the role of ivacaftor in altering chloride ion transport.
4.1. Study limitations
Our study has several important limitations. It is likely that a
CFTR potentiator such as ivacaftor may differentially impact
CFTR activity across tissue types. In this study we examined
the sweat gland and the nasal epithelium. Interestingly, the
changes in sweat chloride (expressed as percentage change
from baseline) paralleled the changes in NPD. Data from the
literature (Fig. 2) also showed that sweat chloride and NPDhave, as a first approximation, a near linear relationship across
clinical phenotypes. A recent study reported a linear relation-
ship between adrenergically mediated sweat secretion among
patients with CF, CF carriers, and normal individuals [29]. The
sweat secretion test could not, however, detect a difference
between pancreatic-sufficient and -insufficient patients with
CF and did not find a difference in most patients with
CFTR-related disorders, whereas sweat chloride concentration
and NPD show a difference between these groups. There is
evidence to suggest that early sweat chloride response may
indicate a higher likelihood of longer-term lung function
change (up to Week 16) in patients treated with a CFTR
potentiator [31]. While while another study found no correla-
tion between changes in sweat chloride concentration and
clinical outcomes [30].
Our analyses were also limited by the small number of
patients in the study. With a larger number of patients,
between-site variability could have been examined. Variability
in NPD testing is a concern in general and is reflected in the
values for the controls (non-CF or normal patients) reported in
the publications in Table 3. The degree of variability from
respected investigators suggests that caution should be exer-
cised when choosing a single value, but the value of −18 mV
reported here was comfortably in the center of the range of
published values.
5. Conclusion
In summary, we developed standardized procedures to
measure sweat chloride in multicenter trials of an orally-
administered CFTR potentiator. Within-patient variance in
sweat chloride was shown to be low for ivacaftor and
placebo-treated patients in this first trial utilizing these new
procedures. Sweat chloride response to treatment was related to
ivacaftor dose. These findings support the use of sweat chloride
testing, a convenient and reproducible biomarker of CFTR
activity, in clinical trials of CF evaluating CFTR potentiators.
We also suggested an approach to estimate change in CFTR
activity using sweat chloride and NPD values taken from
the ivacaftor trial and other published studies. This model
demonstrated that in response to treatment with ivacaftor,
patients achieved a restoration of CFTR activity in the range of
35%–40% of that seen in control patients without CF. Further
exploration of the relationship between sweat chloride concen-
trations, ion transport (as measured by NPD), and clinical
outcome measures such as lung function with CFTR modula-
tors may provide insights into subtleties of ion channel
function.
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Table 3
References for CFTR activity analysis.
Reference Disease phenotype n for
sample
cohort
Sample cohort description Sweat chloride
for sample cohort
(mmol/L)
Sample cohort
Cl-free + iso
response (mV)
Control (non-CF)
zero Cl + iso
response (mV)
CF-PI
Cl-free + iso
response (mV)
% CFTR
calculation
Control (non-CF) group defined
Wilschanski [15] Atypical CF; 9 were PS
and 2 were PI
11 Patients with atypical
CF presentation or
CF suspected
79 (mean from
Table 1)
0.0 –12.0 3.0 20 Control group was normal
individuals or those with non-CF
lung disease (n = 50) and typical
CF patients (n = 31)
Wilschanski [16] Non-CF control 25 No family history of CF
or evidence of pulmonary
or pancreatic disease
20 –29.0 –29.0 4.0 100
CF/obligate heterozygote 21 Fathers or male siblings
of CF patients; confirmed
by genotype
26 –23.0 –29.0 4.0 81.8
Incidental heterozygote 6 Healthy control patients
with CFTR
mutation on 1 allele
34 –27.0 –29.0 4.0 93.9
CBAVD-0 with no mutations 6 Men with CBAVD 22 –22.0 –29.0 4.0 78.8 No family history of CF nor
evidence of pulmonary or
pancreatic disease
CBAVD-1 18 44 –12.0 –29.0 4.0 48.5
CBAVD-2 36 54 –8.0 –29.0 4.0 36.4
CF PS 24 Men with diagnosed CF 73 2.0 –29.0 4.0 6.1
CF PI 26 102 4.0 –29.0 4.0 0
Gilljam [17] R117H (PS); 5 of these are
7 t and one is 5 t
6 Patients with CF
diagnosis in adulthood
72; mean from
Table 4
–5.4 –24.6 3.6 32 Controls not further defined
CF PS 27 66 1.7 −24.6 3.6 6.7
Bishop [18] CF PS 56 68.7 –0.5 –24.6 3.5 14.2
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Patients with idiopathic
pancreatitis
50 healthy controls not further
defined
Obligate heterozygote 16 30.6 –17.7 –24.6 3.5 75.4
Pancreatitis, 2 mutations 6 41 –7.1 –24.6 3.5 37.7
Pancreatitis, 1 mutation 18 34.4 –19.5 –24.6 3.5 81.8
Lebecque [19] Intermediate sweat chloride
with 2 mutations
10 Children with borderline
sweat chloride levels
39.4 –9.4 72 Not defined
Segal [20] Recurrent pancreatitis with
abnormal NPD
7 Recurrent acute
pancreatitis
44 –1.00 –10 2.5 24.1 50 control patients and 50 CF
patients were used for comparison
Wang [21] Chronic rhinosinusitis
patients with 1 mutation
9 Chronic rhinosinusitis
patients with 1 CF
mutation; adults with
nasal or sinus symptoms
× 8 wks or 4 episodes
of recurrent symptoms
in past year
37.4 –11.0 –15.8 5.2 77 10 volunteers not having CF who
had b10 d/y of signs and symptoms
of rhinosinusitis, matched for race,
age range, geographic region, and
socioeconomic status
Pradal [22] CBAVD 12 Patients with CBAVD
and mixed # of mutations
(none in 4; 1 in 7
and 2 in the final)
39 –6 89.6 Controls were patients admitted to
the center with other well
documented diseases or healthy
volunteers
Wallace [23] R553X/R117L 2 80.5 –1.75 –15.7 –0.8 16 12 young people without CF
F508/F508 30 121 –1.3 –0.8
Walker [24] A455E 5 Mild pulmonary disease 80 4.0 –12.0 5 5.8 10 normal patients with no history
of respiratory disease or family
history of CF
G542X, all PI 5 95 2.0 –12.0 5 17.6
Definition of abbreviations: CBAVD = congenital bilateral absence of the vas deferens; CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator; NPD = nasal potential difference; PI = pancreatic
insufficient; PS = pancreatic sufficient.
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Fig. 2. Sweat chloride levels vs. CFTR activity in patients with varying CF genotypes and patients treated with ivacaftor at varying dose levels.*% CFTR activity with
ivacaftor was estimated using NPD measurements taken at the same time as the sweat chloride. Data are shown for 22 cohorts reported in 10 published studies
[15–24], described and tabulated in Table 3.
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